Polomar Health Services (PMHS) Research & Development (2023 - 2026)
Polomar Health Services (PMHS) posted Research & Development of $456419.0 for Q2 2026, up 46.54% on a QoQ basis from $311457.0 in Q1 2026, and up 4243.95% year-over-year from $10507.0 in Q2 2025.
Powered by 
Analysis
Polomar Health Services (PMHS) Research & Development (2023 - 2026) Analysis & Trends
Polomar Health Services has reported Research & Development for 4 years, with the latest figure at $456419.0 in Q2 2026.
- On a quarterly basis, Research & Development rose 4243.95% year-over-year to $456419.0 in Q2 2026; TTM through Jun 2026 was $818382.0, a 2062.23% increase from a year earlier, with the FY2025 full-year figure at $66568.0, up 44.72% from the prior year.
- Research & Development was $456419.0 for Q2 2026 at Polomar Health Services, up from $311457.0 in the prior quarter.
- The five-year high for Research & Development was $456419.0 in Q2 2026, with the low at -$4100.0 in Q4 2024.
- Average Research & Development over 4 years is $74324.5, with a median of $13982.5 recorded in 2024.
- The sharpest annual moves came in 2024 and 2026: Research & Development slumped 1064.71% in 2024, then surged 4243.95% in 2026.
- Over 4 years, Research & Development stood at $425.0 in 2023, then plunged by 1064.71% to -$4100.0 in 2024, then surged by 987.98% to $36407.0 in 2025, then jumped by 1153.66% to $456419.0 in 2026.
- The last three Research & Development figures came in at $456419.0 (Q2 2026), $311457.0 (Q1 2026), and $36407.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 970.00 Mn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 248.30 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 60.90 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 39.02 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 173.00 Mn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 14.75 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -21.86 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 22.16 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 10.66 Mn |
| 10 | Polomar Health Services | 5.66 Mn | 5.48 Mn | 935,916.00 | 456,419.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 456,419.00 |
| Mar 31, 2026 | 311,457.00 |
| Dec 31, 2025 | 36,407.00 |
| Sep 30, 2025 | 14,099.00 |
| Jun 30, 2025 | 10,507.00 |
| Mar 31, 2025 | 19,754.00 |
| Dec 31, 2024 | -4,100.00 |
| Sep 30, 2024 | 11,688.00 |
| Jun 30, 2024 | 14,064.00 |
| Mar 31, 2024 | 13,901.00 |
| Dec 31, 2023 | 425.00 |
| Sep 30, 2023 | 7,273.00 |